At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 233 enrolled
Drug / intervention
5 mg Serlopitant Tablets +1 moredrug
Likely dose
5 mg Serlopitant Tabletsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin
In Brief
A Phase 2 clinical trial evaluating 5 mg Serlopitant Tablets and Matching Placebo Tablets for Pruritus. Completed, enrolled 233 participants across 41 sites.
Detailed Summary
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPruritus
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartJan 2019
First PostedFeb 2019
Primary CompletionDec 2019
Study CompletionJan 2020
TodayJul 2026
First PostedFeb 15, 2019
Enrollment StartJan 22, 2019
Primary CompletionDec 10, 2019
Study CompletionJan 21, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.4 years ago
Interventions
5 mg Serlopitant Tabletsdrug
Serlopitant Tablets
Matching Placebo Tabletsdrug
Placebo Tablets